ReviewTherapeutic advances in hematology2026
The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review.
Review in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a B-cell malignancy involving monoclonal plasma cells that produce nonfunctional immunoglobulins. It is still incurable due to de novo or acquired resistance of malignant cells to standard chemotherapies. Thus, understanding the mechanism of therapeutic resistance is essential to develop better interventions and identifying new therapeutic targets. MM is a heterogeneous disease characterized by complex genetic alterations, which are critical for prognostic stratification. Due to the heterogeneity and clinical challenges associated with MM, there remains a critical need for novel biomarkers to improve both early diagnosis and prognostic accuracy. Antioxidants participate in protecting cancer cells from the damaging effects of oxidative stress by neutralizing reactive oxygen species. These molecules may have their own role in myeloma progression and drug resistance. However, studies reported contradictory ideas regarding the levels and roles of antioxidants in MM. The main aim of this review is to conceptualize the diagnostic, prognostic, and therapeutic significance of common antioxidants for MM. The most common antioxidant systems discussed in this study were DJ-1, glutathione, thioredoxin, and superoxide dismutase. The review revealed that antioxidants are overexpressed in myeloma cells compared to normal plasma cells. This excess expression of antioxidants increases tumor cells' survival and their chemoresistance leads to poor prognosis and short survival of myeloma patients. Thus, antioxidants and their synthesis pathways may have a promising prognostic, diagnostic, and therapeutic role in MM. Vitamin C (ascorbic acid), on the other hand, has a two-faced role in cancer, including MM. It can function as an antioxidant (increase myeloma cell resistance to chemotherapy) or pro-oxidant (enhance the therapeutic effect of myeloma drugs), depending on its dose and route of administration. Pharmacological (ultra-high) doses of vitamin C administered intravenously may act as a pro-oxidant that can selectively kill myeloma cells by elevating the cellular labile iron pool and generating extracellular H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.